The concept of using the body's own immune system to combat cancer, known as immunotherapy, has undergone significant evolution over the past decade. Initially deemed a novel approach for treating a limited patient demographic with advanced cancer types, immunotherapy now stands as a
Recent advancements in healthcare are uncovering surprising new uses for existing medications, and one prominent example is Ozempic (semaglutide). Originally hailed for its effectiveness in treating diabetes and aiding in weight loss, Ozempic is now being investigated for its potential to address
In the rapidly evolving landscape of biopharmaceutical manufacturing, capturing real-time data has become pivotal in optimizing bioreactor performance and producing high-quality products. Inline monitoring technologies are at the forefront of this transformation, offering real-time surveillance and
The biopharma industry is grappling with a persistent wave of layoffs as companies navigate financial constraints and strategic realignments. Despite hopes for a reprieve in 2024, the sector saw a 3% increase in layoffs compared to the previous year. This trend underscores the ongoing challenges
The latest study from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center provides compelling evidence that CAR T cell therapy does not induce secondary cancers. This finding comes from an extensive analysis of data involving over 700
In a surprising move, Rentschler Biopharma announced its decision to withdraw from the cell and gene therapy (CGT) business at its Stevenage, UK facility, marking a significant shift in the company's strategic focus. This decision comes despite recent investments in building advanced
